NCT03862807: A reported trial by Alnylam Pharmaceuticals
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03862807 |
|---|---|
| Title | An Open-label Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of Patisiran-LNP in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) With Disease Progression Post-Orthotopic Liver Transplant |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 27, 2019 |
| Completion date | Oct. 6, 2020 |
| Required reporting date | Oct. 6, 2021, midnight |
| Actual reporting date | Oct. 6, 2021 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |